2-AMINO-6-METHYLHEPTANE

Weight Loss Powders 2-AMINO-6-METHYLHEPTANE CAS 543-82-8 DMHA

 

Product Name:2-AMINO-6-METHYLHEPTANE
Synonyms:1,5-dimethyl-hexylamin;2-Heptanamine, 6-methyl-;2-Heptylamine, 6-methyl-;2-Isooctylamine;2-Methyl-6-aminoheptane;2-Metil-6-amino-eptano;6-Amino-2-methylheptane;6-methyl-2-heptanamin
CAS:543-82-8
MF:C8H19N
MW:129.24
EINECS:208-851-1
Product Categories:Amines;Building Blocks;C8;Chemical Synthesis;Nitrogen Compounds;Organic Building Blocks;Aliphatics;Inhibitors;Intermediates;Fine chemicals
Boiling point: 154-156 °C(lit.)
Density : 0.767 g/mL at 25 °C(lit.)
Refractive index : n20/D 1.422(lit.)
Fp : 120 °F
Storage temp. : Flammables area
Chemical Properties : white powders
Uses: 1,5-Dimethylhexylamine is an aliphatic secondary amine which shows leucine aminotransferase inhibition. 1,5-Dimethylhexylamine is used in the preparation of glycosyl β-amino acids with antitubercular activity.

Weight loss Medicine

L(-)-Carnitine CAS:541-15-1
Rimonabant CAS:168273-06-1
Synephrine CAS:94-07-5
LORCASERIN CAS : 856681-05-5
Orlistat CAS:96829-58-2
Cetilistat CAS : 282526-98-1
N-stearoylvanillylamide CAS : 58493-50-8
DNP CAS: 1011-73-0
T3 / Liothyronine sodium CAS: 55-06-1
1,3-DiMethylpentanaMine Hydrochloride DMAA CAS: 13803-74-2
DMHA 1,5-DiMethylhexylaMine CAS: 543-82-8
DIMETHYL BENZYLAMINE DMBA / DMBZA CAS: 57-97-6
1,3-dimethyl-butylamine citrate / AMP Citrate
2-Dimethylaminoethanol (+)-bitartrate salt / DMAE bitartrate CAS: 5988-51-2
REVERSE T3 CAS:5817-39-0
3,5-Diiodo-L-thyronine / T2 CAS:1041-01-6
3,3’,5-triiodothyronine / T3 CAS: 6893-02-3
L-Thyroxine T4 CAS: 51-48-9
Sodium levothyroxine CAS: 25416-65-3
Levothyroxine sodium CAS: 55-03-8

 

Send Inquiry

DNP

Pharmaceutical Fat Loss Sodium 2, 4-Dinitrophenate CAS 1011-73-0 DNP

 

Product name : Sodium 2,4-dinitrophenate
Synonyms : Sodium 2,4-dinitrophenate;SODIUM-2,4-DINITROPHENOL;SODIUM 2,4-DINITROPHENOLATE;2,4-DINITROPHENOL SODIUM SALT;
2,4-dinitrophenol,sodiumsalt(as;2,4-dinitrophenol,sodiumsalt(asimpurity);2,4-dinitro-phenosodiumsalt;Dinitrophenol,sodiumsalt
Appearance : Deep Yellow Crystal Powder
Purity : 99%
CAS : 1011-73-0
EINECS: 213-786-7
MF : C6H3N2NaO5
MP : 114-115° C
MW : 206.09
Storage : Store in cool and dry area and keep away from direct sunlight.
Strictly prohibit being putted or transported together with toxic and hazardous.
It is non-dangerous goods, as general chemical for transportation.
Handle gently and prevent the sun and rain.
Shelf life : 2 Years
Package : 25kg/Bag

 

DNP Description

Deep yellow crystal powder, it is faint soluble in water, soluble in organic solvents, such as ethyl alcohol, diethyl and benzene.

Stable in room temperature, has possibility to explosive when meet naked flame or be stroked.
Application

Sodium 2, 4-dinitrophenolate can quickly infiltrate through the plant body, quicken the speed of nutrition absorption of plant roots, promote plant sprouting, rooting and avoid falling blooms and fruits
1. To be used as plant-growth regulator;
2. To be used as intermediate Chemicals.

 

Usage of DNP Powder

2,4-Dinitrophenol (DNP) is reported to cause rapid loss of weight, but unfortunately is associated with an unacceptably high rate of significant adverse effects .

DNP is sold mostly over the internet under a number of different names as a weight loss/slimming aid. It causes uncoupling of oxidative phosphorylation; the classic symptom complex associated with toxicity of phenol-based products such as DNP is a combination of hyperthermia, tachycardia, diaphoresis and tachypnoea, eventually leading to death .

Fatalities related to exposure to DNP have been reported since the turn of the twentieth century. To date, there have been 62 published deaths in the medical literature attributed to DNP. In this review, we will describe the pattern and pathophysiology of DNP toxicity and summarise the previous fatalities associated with exposure to DNP .

 

Recommend dosage of DNP Powders

The recommend dosage is between 2-6mg/kg-bw per day for crystalline DNP and 4-10mg/kg-bw for powdered DNP.

A beginner should always start off at the low end to assess tolerance. Trying this for the first time 2 weeks before a competition can be disastrous. A 220lb man is 100kg exactly. This means that if he is a first time user of crystalline DNP then he should take 200mg per day. I suggest staying with this dose for at least 3 days to keep it safe, then slowly increase the dosage. 400mg/day can be used, but never take it all at once. Always split up the doses as far as possible, so for 400mg/day that would mean taking 1 200mg capsule every 12 hours.

Only on rare occasions should someone attempt 600mg/day with the crystalline capsules unless it’s used by a very experi- enced user and all the vital signs are closely monitored. Cycle length depends largely on the individual. At first it was thought that a DNP cycle should be limit- ed to 10 days at the most because the thyroids shuts down and t4 to t3 conversion in the liver becomes nil, however, this is not the case. 10 days is a very arbitrary number .

A person taking 200mg/day would have almost completely normal thyroid function at day 10 whereas if s/he took 600mg/day, t3 would be non existent after 3 days. While the t3 hormone plays a very large role in determining fat loss, it should not be a big concern while on DNP because the fat burning capabilities of DNP will more than compensate for the suppressed t3 levels. An advantage to suppressed t3 levels is that the body will burn much less muscle while still burning fat on DNP. Normal t3 and thyroid function is restored within a week of stopping DNP .

Cetilistat

Health Care Raw Powders Cetilistat 282526-98-1 for Weight Loss

 

Quick Details for Cetilistat

Product Name: Cetilistat
Synonyms: cetilistat;Cetilistat(Alt-962);Cetilstat;2-(Hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one;2-(Hexadecycloxy)-6-methyl-4H-3,1-benzoxazin-4-one;4H-3,1-Benzoxazin-4-one,2-(hexadecyloxy)-6-Methyl-;Xinli orlistat
CAS: 282526-98-1
MF: C25H39NO3
MW: 401.58
Product Categories: Aromatics;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;API;Cetilistat
Density : 1.02
Chemical Properties : Off-white Cryst
Usage : A novel pancreatic lipase inhibitor for the treatment of obesity in both diabetic and non-diabetic patients.

 

Cetilistat Description

Cetislim containing the active ingredient cetilistat is considered a lipase inhibitor type of medication. The medication works by blocking the metabolization of fat within food so you do not digest it and the undigested fat will be passed through the body in bowel movement. The capsules should be used along with a low calorie, low fat diet and a proper exercise program to treat obesity. Reducing calorie intake and weight maintenance can help prevent and treat conditions such as high cholesterol, diabetes, hypertension and heart disease.

Cetilistat is a drug designed to treat obesity. It acts in the same way as the older drug orlistat (Xenical) by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested.

In human trials, cetilistat was shown to produce similar weight loss to orlistat, but also produced similar side effects such as oily, loose stools, fecal incontinence, frequent bowel movements, and flatulence. It is likely that the same precautions would apply in that absorption of fat-soluble vitamins and other fat-soluble nutrients may be inhibited, requiring vitamin supplements to be used to avoid deficiencies.

 

Cetilistat Applications

Cetilistat is a weight loss drug used in combination with a low calorie diet. It works by blocking a substantial amount of fat from being digested and absorbed into the body. This medicine is classified as a lipase inhibitor and it works directly on the digestive system where it blocks the action of a lipolytic enzyme called lipase. These lipases are what the body uses to digest the fat.

However, when this medicine is administered alongside a meal, it binds to the lipases, thereby inhibiting them from breaking down the fat. Fats which are not hydrolyzed are instead excreted in the feces, resulting in increased fecal fat excretion and reduced fat absorption. When used together with a reduced calorie diet, it can help improve weight loss and make it easier for overweight patients to get back in shape, thereby boosting the chances of successful weight loss.

 

Send Inquiry

Orlistat

Novel Weight Loss Lipid-lowering Drugs Orlistat CAS 96829-58-2

 

Quick Details for Orlistat

Product Name: Orlistat
Synonyms: (S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID (S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]-DODECYL ESTER;RO-18-0647;(-)-TETRAHYDROLIPSTATIN;ORLISTAT;N-FORMYL-L-LEUCINE (1S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]DODECYL ESTER;XENICAL;(-)-Tetrahydrolipstatin(EquivalentToOrlistat);Orlipastat
CAS: 96829-58-2
MF: C29H53NO5
MW: 495.73
Product Categories: Pharmaceutical Raw Materials;Miscellaneous Biochemicals;API;Antiobesity Agent;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Amino Acids & Derivatives;Heterocycles;ACTOS;Other APIs;Lipid-lowering medicine reducing weight
Melting point : <50 °C
Storage temp. : 2-8°C
Chemical Properties : Off-White Solid
Usage : An antiobesity agent. A pancreatic lipase inhibitor. Antiobesity agent.
Usage : antidiabetic
Usage : Orlistat is an antiobesity agent. Orlistat is an pancreatic lipase inhibitor.
Usage : Tetrahydrolipstatin (orlistat) is a semi-synthetic derivative of lipstatin, a metabolite isolated from Streptomyces toxytricini. Tetrahydrolipstatin acts as a potent, irreversible inhibitor of pancreatic lipase. In vivo, it blocks the absorption of triglycerides while allowing fatty acid absorption. Tetrahydrolipstatin is widely used for the treatment of obesity.

 

Orlistat Pharmacological effects

Orlistat belongs to lipase inhibitor class weight-loss drugs, which is the hydration derivatives of lipstatin, being able to reduce the absorption of food fats so that the weight will get lost. This product has a potent and selective inhibitory effect on gastric lipase and pancreatic lipase with no influence on other kinds of digestive enzymes (amylase, trypsin, and chymotrypsin) and phospholipase without affecting the absorption of carbohydrates, protein and phospholipids. The drug is not absorbed by the gastrointestinal tract with its inhibition on lipase being reversible.

Orlistat can form covalent bonds with the active serine sites of the gastric lipase and the pancreatic lipase in the stomach and small intestine cavity, resulting in inactivation of the enzymes, inhibiting the triglyceride hydrolysis so that the monoglyceride and free fatty acid intake will decrease, thereby controlling the body weight. The pharmacological activity of orlistat is dose-dependent with a therapeutic dose of orlistat (120 mg / day, taken at mealtime) in combination with a low-calorie balanced diet being capable of reducing 30% of fat absorption in the diet. Studies on normal-weight and obese volunteers have shown that orlistat is not substantially absorbed by the body and that the concentration of the drug in the plasma is very low. After oral administration of a single dose (maximal dose of 800 mg), the plasma concentration of orlistat within 8 hours is lower than 5 ng / ml.

Generally under the treatment dose, the body has a low systemic absorption of the orlistat without accumulation during short-term treatment. In vitro experiments, orlistat has an as high as over 99% binding rate to the plasma protein (lipoprotein, albumin as the major binding protein). Orlistat can rarely bind to red blood cells. Studies in obese patients show that orlistat, which is seldom absorbed, has two major metabolites in plasma, M1 (hydrolyzate of the 4-lactone ring) and M3 (M1 attached with a N-formyl-l Lysine lysis product) account for 42% of the total plasma concentration. M1 and M3 have extremely week inhibitory effect on lipase. The unabsorbed orlistat was mainly excreted from the feces, accounting for 97% of the dose taken, 83% of which were prototype drugs, and the cumulative renal excretion amount of orlistat and its metabolites was less than 2%. It needs 3 to 5 days for thorough excretion (feces and urine) of drugs. Both M1 and M3 can be excreted through bile.
This product also has an effect of regulating blood lipids: being able to reduce serum triglyceride (TG) and the low density lipoprotein cholesterol (LDL-C) and increase the proportion of high-density lipoprotein and low-density lipoprotein in the serum of obesity patients.

 

Dosage and Usage

This combination of Xenical (orlistat) with mild low-calorie diet is applicable to obese and overweight patients, including for the long-term treatment of patients who have been associated with obesity-related risk factors. This product has long-term effects of weight control (weight loss, weight maintenance and prevention of rebound). Administration of orlistat can reduce the incidence of obesity-related risk factors and other obesity-related diseases, including hypercholesterolemia and type II diabetes.

Adults: The recommended dose is taking a 120 mg capsule during meal or within one hour after meal. If a meal is not into the food or no fat, you can omit a medication. Long-term use of treatment (including weight control and risk factors for improvement) is sustainable.

The patient’s diet should be nutritionally balanced with slightly low heat. There is about 30% of heat coming from fat. The food should be rich in fruits and vegetables. The intake of fats, carbohydrates and protein should be distributed in three meals a day. There is no evidence that over three times daily /120mg per time can enhance the efficacy. No dose adjustment is required for the elderly.

Send Inquiry

Synephrine

Oxedrine Weight Loss Pharmaceutical Raw Material Synephrine 94-07-5

 

Quick Details for Synephrine

Product name : Synephrine
CAS : 94-07-5
MF : C9H13NO2
MW : 167.21
EINECS : 202-300-9
Mp : 187 °C (dec.)(lit.)
Storage temp : 2-8°C
Chemical Properties : Off-White to Beige Powder
Usage : Vasopressor. Used for shock, heart failure, treatment of bronchial asthma and operation anesthesia and hypotension, collapse and shock, hypotension, body position.

 

Synephrine Description

Synephrine is the main active ingredient in lime fruit, which can effectively prevent the excess energy (heat accumulation), the wind Qi, warm the stomach and promote appetite and accelerate The new supersedes the old. Lime could theoretically accelerate fat metabolism and not like the use of Ephedra patients that appear to influence the adverse side effects of cardiovascular. It is also a mild fragrance expectorant, a kind of calm the nerves and laxative agent and in the treatment of constipation.

 

Avail Dosage

Users can expect variable effects include consumption of excess heat, reduce appetite and increase satiety, and these may cause weight loss. A study of the dog’s study also proposed synephrine in what are called special fatty tissue brown fat tissue in can enhance the metabolic rate. Citrus aurantium extract synephrine as standard has been recommended. 4-20mg daily dose of synephrine as containing 200-600mg standard of citrus aurantium extract products (3-6% synephrine) typical dose.

 

Send Inquiry

LORCASERIN

Safety Weight Loss Drugs LORCASERIN CAS 616202-92-7 for Fat Burning

 

Quick Details for LORCASERIN

Product Name: LORCASERIN
Synonyms: LORCASERIN;(R)-8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine;Apd 356;Apd356;Apd-356;Ar-10a;Unii-637E494o0z;(1R)-8-Chloro-2,3,4,5-tetrahydro-1-Methyl-1H-3-benzazepine
CAS: 616202-92-7
MF: C11H14ClN
MW: 195.692
Product Categories: Amines;Aromatics;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
Boiling point : 288 ºC
Density : 1.075
Appearance : White crystalline powders
Usage : Diet pills . A novel selective 5-HT2C-receptor agonist for the treatment of obesity.

 

Weight loss drugs

Lorcaserin is a new drug for the treatment of obesity , belonging to oral potent selective serotonin 2C receptor agonists, lorcaserin hydrochloride is successfully developed by the US company Arena, on June 27, 2012 by the US FDA it is approved for marketing, as adjuvant therapy for obesity or merge with at least one weight-related complications in overweight adults in low-calorie diet and exercise basis . Clinical studies show that the drug can reduce weight of obesity and overweight patients ,it can improve obesity-related metabolic parameters, and it is well tolerated. Lorcaserin affinity for the 5-HT2c 100 times higher than the 5-HT2B (valvular heart disease risk) ,it has good safety,it is the first FDA-approved weight-loss drug after 1999 . In a year of Lorcaserin treatment, the average weight loss ranges from 3 to 3.7 percent.

 

LORCASERIN Description

Belviq(Lorcaserin hydrochloride) is an FDA-approved prescription weight-loss medication that, when used with diet and exercise, can help some overweight? adults with a weight-related medical problem, or obese adults, lose weight and keep it off. It is not known if BELVIQ when taken with other prescription, over-the-counter, or herbal weight-loss products is safe and effective. It is not known if BELVIQ changes your risk of heart problems, stroke, or death due to heart problems or stroke.

 

LORCASERIN Applications

Belviq is a serotonin 2C receptor agonist. It hasbeen shown to decrease food consumption and promote satiety by selectivelyactivating serotonin 2C receptors in the brain.

Belviq is specifically indicated as an adjunct to a reduced-calorie diet andincreased physical activity for chronic weight management in clinically obeseadults (BMI of 30 kg/m2 or greater) and overweight adults (BMI of 27 kg/m2 orgreater) with at least one weight-related comorbid condition.

Belviq is supplied as a tablet designed for oral administration. The recommendeddose is one 10mg tablet twice daily. Use of Belviq should be discontinued if 5%weight loss is not achieved by week 12 of treatment.

Lorcaserin has good tolerability and safety, lorcaserin is used in non-diabetic patients, the most common adverse reactions are headache, dizziness, fatigue, nausea, dry mouth and constipation. This product is used in patients with diabetes, common adverse reactions are headache, back pain, cough, low blood sugar and fatigue.studies have found that lorcaserin and placebo are Similar in the proportion of serious adverse reactions, lorcaserin does not increase the incidence of valvular heart disease. After lorcaserin treatment , the incidence of depression is lower , the research shows that the proportion of depression led by lorcaserin 10mgbid, 10mgqd and placebo are 1.9%, 1.1% and 1.8%, emotional low incidence rates are 0.6%, 0.9% and 0.9%, the proportion of suicidal thoughts are 0.9%, 0.6% and 0.7% .the product is pregnancy X-class , pregnant women are disabled; whether this product is secreted by milk is unknown, breast-feeding women need to weigh on the use of the drug; this product is not recommended for children.

 

Send Inquiry